2.20

6.28% 0.13

After Hours: 2.18 -0.02 -0.91%

Compass Therapeutics Inc (CMPX)

Overview News Price History Financials Discussions Forecast

Compass Therapeutics Inc stock is traded at $2.20, with a volume of 4.72M. It is up +6.28% in the last 24 hours and down -56.26% over the past month. Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Previous Close:

$2.07

Open:

$2.04

24h Volume:

4.72M

Relative Volume:

0.68

Market Cap:

$396.19M

Revenue:

$850.00K

Net Income/Loss:

$-68.17M

P/E Ratio:

-5.345

EPS:

-0.4116

Net Cash Flow:

$-53.29M

1W Performance:

+21.55%

1M Performance:

-56.26%

6M Performance:

-59.18%

1Y Performance:

+5.26%

1-Day Range:

$2.01

$2.225

1-Week Range:

$1.78

$2.225

52-Week Range:

$1.61

$6.88

Compass Therapeutics Inc Stock (CMPX) Company Profile

Name

Compass Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

617-500-8099

Address

80 GUEST STREET, BOSTON

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

CMPX's Discussions on Twitter

Compare CMPX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CMPX Compass Therapeutics Inc	2.20	372.78M	850.00K	-68.17M	-53.29M	-0.4116
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-13-26	Initiated	Craig Hallum	Buy
Jan-05-26	Initiated	William Blair	Outperform
Dec-03-25	Initiated	Canaccord Genuity	Buy
Dec-03-25	Initiated	Cantor Fitzgerald	Overweight
Dec-03-25	Initiated	Citizens JMP	Mkt Outperform
Jul-01-25	Resumed	Raymond James	Outperform
Apr-02-25	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-24-25	Initiated	Guggenheim	Buy
Feb-19-25	Initiated	Piper Sandler	Overweight
Dec-23-24	Initiated	D. Boral Capital	Buy
Nov-15-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jan-31-23	Initiated	Jefferies	Buy
Jan-27-23	Initiated	Stifel	Buy
May-23-22	Resumed	H.C. Wainwright	Buy
Mar-15-22	Initiated	Ladenburg Thalmann	Buy
Jan-19-22	Initiated	B. Riley Securities	Buy
Dec-22-21	Initiated	Raymond James	Outperform
Dec-20-21	Initiated	SVB Leerink	Outperform
Dec-15-21	Initiated	Wedbush	Outperform

View All

Compass Therapeutics Inc Stock (CMPX) Latest News

May 21, 2026

Compass Therapeutics reports phase 1 data for CTX-8371 By Investing.com - Investing.com South Africa

May 21, 2026

Compass Therapeutics reports phase 1 data for CTX-8371 - Investing.com UK

May 21, 2026

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting - Investing News Network

May 21, 2026

Compass Therapeutics Announces Promising Phase 1 Results for CTX-8371, Innovative Dual Checkpoint Blocker in Advanced Malignancies - Quiver Quantitative

May 21, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc.CMPX - PR Newswire

May 21, 2026

May 20, 2026

CMPX News | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill

May 20, 2026

May 19, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass ... - Caledonian Record

May 19, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Thera - The National Law Review

May 14, 2026

CMPX Technical Analysis | Trend, Signals & Chart Patterns | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill

May 14, 2026

May 13, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Compass Therapeutics, Inc. (CMPX) And Encourages Shareholders to Reach Out - ACCESS Newswire

May 13, 2026

2026-05-13 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Compass Therapeutics, Inc. (CMPX) And Encourages Shareholders to Reach Out | NDAQ:CMPX | Press Release - Stockhouse

May 13, 2026

May 12, 2026

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - FinancialContent

May 12, 2026

TradingKey - TradingKey

May 12, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

May 12, 2026

2026-05-12 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Compass Therapeutics, Inc. (CMPX) and Encourages Shareholders to Learn More About the Investigation | NDAQ:CMPX | Press Release - Stockhouse

May 12, 2026

Compass Therapeutics to Participate in Upcoming May Investor Events - The Manila Times

May 12, 2026

May 11, 2026